Head-To-Head Contrast: HeartBeam (BEAT) vs. Its Competitors

HeartBeam (NASDAQ:BEAT) is one of 58 publicly-traded companies in the “MEDICAL INFO SYS” industry, but how does it compare to its competitors? We will compare HeartBeam to related businesses based on the strength of its earnings, valuation, dividends, institutional ownership, analyst recommendations, profitability and risk.

Profitability

This table compares HeartBeam and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-571.06%	-353.09%
HeartBeam Competitors	-683.81%	-121.85%	-18.99%

Insider and Institutional Ownership

7.8% of HeartBeam shares are owned by institutional investors. Comparatively, 43.7% of shares of all “MEDICAL INFO SYS” companies are owned by institutional investors. 18.0% of HeartBeam shares are owned by company insiders. Comparatively, 17.0% of shares of all “MEDICAL INFO SYS” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

HeartBeam has a beta of -0.86, meaning that its share price is 186% less volatile than the S&P 500. Comparatively, HeartBeam’s competitors have a beta of 2.02, meaning that their average share price is 102% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for HeartBeam and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1	2	4	1	2.63
HeartBeam Competitors	654	1034	2243	54	2.43

HeartBeam currently has a consensus target price of $4.80, suggesting a potential upside of 478.31%. As a group, “MEDICAL INFO SYS” companies have a potential upside of 60.91%. Given HeartBeam’s stronger consensus rating and higher probable upside, research analysts plainly believe HeartBeam is more favorable than its competitors.

Valuation & Earnings

This table compares HeartBeam and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
HeartBeam	N/A	-$21.01 million	-1.34
HeartBeam Competitors	$498.32 million	-$52.57 million	7.84

HeartBeam’s competitors have higher revenue, but lower earnings than HeartBeam. HeartBeam is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

HeartBeam competitors beat HeartBeam on 7 of the 13 factors compared.

About HeartBeam

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.